142 related articles for article (PubMed ID: 37979411)
1. The impact of COVID-19 on a Southern Chinese cohort with neuromyelitis optica spectrum disorders.
Zhong J; Wu Y; Zhou S; Liu C; Wen Y; Liang M; Li T; Lu T; Lv S; Gong Z; Lao D; Cao X; Tang Y; Huang W
Mult Scler Relat Disord; 2024 Jan; 81():105120. PubMed ID: 37979411
[TBL] [Abstract][Full Text] [Related]
2. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
4. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders.
Amaral JM; Talim N; Kleinpaul R; Lana-Peixoto MA;
Mult Scler Relat Disord; 2020 Jun; 41():102045. PubMed ID: 32179485
[TBL] [Abstract][Full Text] [Related]
5. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
[TBL] [Abstract][Full Text] [Related]
6. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
Pathomrattanapiban C; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S
Mult Scler Relat Disord; 2022 Jul; 63():103882. PubMed ID: 35598463
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434
[TBL] [Abstract][Full Text] [Related]
10. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.
Du C; Zeng P; Han JR; Zhang TX; Jia D; Shi FD; Zhang C
Front Immunol; 2021; 12():660230. PubMed ID: 34745082
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
Front Immunol; 2022; 13():873576. PubMed ID: 35432315
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
[TBL] [Abstract][Full Text] [Related]
14. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.
Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M
Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925
[TBL] [Abstract][Full Text] [Related]
16. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
Paybast S; Emami A; Baghalha F; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Sep; 65():103960. PubMed ID: 35763914
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
18. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.
Drulovic J; Martinovic V; Basuroski ID; Mesaros S; Mader S; Weinshenker B; Pekmezovic T
Mult Scler Relat Disord; 2019 Nov; 36():101413. PubMed ID: 31586803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
